The FDA assessed the security and efficiency of atidarsagene autotemcel depending on information from 37 kids who been given atidarsagene autotemcel in two solitary-arm, open up-label medical trials and in an expanded entry system.[seven] Young children who obtained treatment with atidarsagene autotemcel have been in comparison with untreated child